Thyroid Peroxidase Antibodies in Non-Autoimmune Hyperthyroidism Treated with Radioactive Iodine

Abstract

Introduction: Earlier studies suggest increased serum levels of thyroid peroxidase antibodies (TPOAb) in some cases with non-autoimmune hyperthyroidism. The aim of the study was to assess the incidence of hypothyroidism in patients with nodular toxic goitre and toxic adenoma at 12 months after radioactive iodine therapy in the relation to TPOAb levels.

Patients & Measurements: The study comprised 100 patients (83 females; 17 males) treated with radioactive iodine therapy. Serum concentrations of thyrotropin, free thyroxin, TPOAb, and anti-TSH receptor antibodies were assessed at baseline and 12 months after radioactive iodine therapy.

Results: High TPOAb level (>60.0 IU/mL) was found in 27% of patients at baseline and 32% at the follow-up. Baseline TPOAb values were higher in subjects with coexisting non-thyroid autoimmune disease (p=0.041). After radioactive iodine therapy, the mean TPOAb level increased in patients with normal baseline TPOAb (p=0.03) and the rates of euthyroidism and hypothyroidism were 61 and 34%, respectively. The rate of hypothyroidism after radioactive iodine therapy was not significantly different in groups with normal and high baseline TPOAb.

Conclusions: 27% of patients with non-autoimmune hyperthyroidism were positive for TPOAb. However, baseline TPOAb level did not influence the rate of hypothyroidism at 12 months after radioactive iodine therapy. Our results suggest a more close surveillance after radioactive iodine therapy of patients harboring these antibodies.

Key words

non-autoimmune hyperthyroidism - radioactive iodine therapy - thyroid peroxidase antibody - hypothyroidism

• References

• 1 Stokkel MP, Handkiewicz Junak D, Lassmann M et al. EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging 2010; 37: 2218-2228
• 2 Bahn RS, Burch HB, Cooper DS et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011; 21: 593-646
• 3 Dunkelmann S, Wolf R, Koch A et al. Incidence of radiation-induced Graves’ disease in patients treated with radioiodine for thyroid autonomy before and after introduction of a high-sensitivity TSH receptor antibody assay. Eur J Nucl Med Mol Imaging 2004; 31: 1428-1434
• 4 Boi F, Piga M, Loy M et al. Hypothyroid Hashimoto’s thyroiditis with scintigraphic and echo-color Doppler features mimicking autonomous adenoma. J Endocrinol Invest 2002; 25: 469-472
• 5 Bjoro T, Holmen J, Krüger O et al. Prevalence of thyroid disease, thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected population. The Health Study of Nord-Trondelag (HUNT). Eur J Endocrinol 2000; 143: 639-647
• 6 Taubner K, Schubert G, Pulzer F et al. Serum concentrations of anti-thyroid peroxidase and anti-thyroglobulin antibodies in children and adolescents without apparent thyroid disorders. Clin Biochem 2014; 47: 3-7
• 7 Prummel MF, Wiersinga WM. Thyroid peroxidase autoantibodies in euthyroid subjects. Best Pract Res Clin Endocrinol Metab 2005; 19: 1-15
• 8 Bera S, Gupta S, Dutta SK et al. Anti-thyroid peroxidase antibody level in thyroid nodules: with special reference to thyroid neoplasia. Int Res J Pharm 2013; 4: 150-152
• 9 Le Moli R, Wesche MF, Tiel-Van Buul MM et al. Determinants of longterm outcome of radioiodine therapy of sporadic non-toxic goitre. Clin Endocrinol (Oxf) 1999; 50: 783-789
• 10 Rizzo M, Rossi RT, Bonaffini O et al. Increased annual frequency of Hashimoto’s thyroiditis between years 1988 and 2007 at a cytological unit of Sicily. Ann Endocrinol (Paris) 2010; 71: 525-534
• 11 Amouzegar A, Bakhtiyari M, Mansournia MA et al. Sex- and age-specific reference values and cutoff points for TPOAb: Tehran Thyroid Study. Thyroid 2016; 26: 458-465
• 12 McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine 2012; 42: 252-265
• 13 Bonnema SJ, Hegedüs L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev 2012; 33: 920-980
• 14 Pisarek M, Baczyk M, Gryczyńska M et al. Autoimmunization and multinodular large toxic goiter therapy using repeated doses of 131I. Pol Arch Med Wewn 2006; 115: 545-550
• 15 Boj Carceller D, Liévano Segundo P, Navarro Beltrán P et al. Short-term results of treatment with I-131 in patients with multinodular goiter: effect of the associated degree of hyperthyroidism and other variables. Rev Esp Med Nucl 2011; 30: 156-161
• 16 Bolusani H, Okosieme OE, Velagapudi M et al. Determinants of long-term outcome after radioiodine therapy for solitary autonomous thyroid nodules. Endocr Pract 2008; 14: 543-549
• 17 Tzavara I, Tzanela M, Vlassopoulou B et al. Long term thyroid function after 131I treatment for toxic adenoma. Hormones 2002; 1: 99-103
• 18 Huysmans DA, Corstens FH, Kloppenborg PW. Long term follow up in toxic solitary autonomous thyroid nodules treated with radioactive iodine. J Nucl Med 1991; 32: 27-30
• 19 Sawicka N, Sowiński J. Correlation between thyroid volume and humoral thyroid autoimmunity after radioiodine therapy in Graves’ disease. Endokrynol Pol 2002; 63: 10-13
• 20 Ahmad AF, Ahmad M, Young ET. Objective estimates of the probability of developing hypothyroidism following radioactive iodine treatment of thyrotoxicosis. Eur J Endocrinol 2002; 146: 767-775
• 21 Braga M, Walpert N, Burch HB et al. The effect of methimazole on cure rates after radioiodine treatment for Graves’ hyperthyroidism: a randomized clinical trial. Thyroid 2002; 12: 135-139
• 22 Andrade VA, Gross JL, Maia AL. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves’ hyperthyroidism: one-year follow-up of a prospective, randomized study. J Clin Endocrinol Metab 2001; 86: 3488-3493
• 23 Goldstein R, Hart IR. Follow up of solitary autonomous thyroid nodules treated with 131-I. New Engl J Med 1983; 309: 1473-1476
• 24 Puille M, Klett R, Steiner D et al. Influence of dose rate on therapeutic success of radioiodine therapy of functional thyroid autonomy. Nucl Med Commun 2005; 26: 727-730
• 25 Intenzo CM, Capuzzi DM, Jabbour S et al. Scintigraphic features of autoimmune thyroiditis. Radiographics 2001; 21: 957-964
• 26 Cakir M. Marine-Lenhart syndrome. J Natl Med Assoc 2005; 97: 1036-1038
• 27 Ruggeri RM, Campenni A, Sindoni A et al. Association of autonomously functioning thyroid nodules with Hashimoto’s thyroiditis: study on a large series of patients. Exp Clin Endocrinol Diabetes 2011; 119: 621-627
• 28 DeGroot LJ. Graves’ Disease and the manifestations of thyrotoxicosis. [Updated 2015 Jul 11]. . In: De Groot LJ, Beck-Peccoz P, Chrousos G. (eds.) Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000 . Available from http://www.ncbi.nlm.nih.gov/books/NBK285567/
• 29 Nygaard B, Faber J, Veje A et al. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy. Thyroid 1999; 9: 477-441
• 30 Custro N, Ganci A, Scafidi V. Relapses of hyperthyroidism in patients treated with radioiodine for nodular toxic goiter: relation to thyroid autoimmunity. J Endocrinol Invest 2003; 26: 106-110
• 31 Sheehan MT, Doi SAR. Transient hypothyroidism after radioiodine for Graves’ disease: challenges in interpreting thyroid function tests. Clin Med Res 2016; 14: 40-45
• 32 Freitas JE. Therapeutic options in the management of toxic and nontoxic goiter. Semin Nucl Med 2000; 30: 88-97
• 33 Laurberg P, Wallin G, Tallstedt L et al. TSH-receptor autoimmunity in Graves’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 2008; 158: 69-75
• 34 Lazúrová I, Benhatchi K, Rovenský J et al. Autoimmune thyroid disease and autoimmune rheumatic disorders: a two-sided analysis. Ann NY Acad Sci 2009; 1173: 211-216
• 35 Al-Awadhi AM, Olusi S, Hasan EA et al. Frequency of abnormal thyroid function tests in Kuwaiti Arabs with autoimmune diseases. Med Princ Pract 2008; 17: 61-65
• 36 Wiersinga WM. Clinical relevance of environmental factors in the pathogenesis of autoimmune thyroid disease. Endocrinol Metab (Seoul) 2016; 31: 213-222